LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Siemens Launches New Combination Tests for SARS-CoV-2 and Seasonal Respiratory Pathogens

By LabMedica International staff writers
Posted on 16 Sep 2022
Image: CLINITEST Rapid COVID-19 + Influenza Antigen Test delivers reliable results in 15 minutes (Photo courtesy of Siemens)
Image: CLINITEST Rapid COVID-19 + Influenza Antigen Test delivers reliable results in 15 minutes (Photo courtesy of Siemens)

Siemens Healthineers (Erlangen, Germany) has announced the release of its new CE-marked FTD SARS-CoV-2/FluA/FluB/HRSV Assay, a PCR test, and the CLINITEST Rapid COVID-19 + Influenza Antigen Test.

Validated on Siemens’ VERSANT kPCR Molecular System, the new FTD SARS-CoV-2/FluA/FluB/HRSV Assay combines the company’s FTD SARS-CoV-23 and FTD Flu/HRSV Assays. The new assay enables comprehensive and semi-automated molecular testing for seasonal respiratory pathogens. The combination PCR test detects and differentiates between clinically relevant viruses: SARS-CoV-2, Influenza A, Influenza B, and HRSV A/B. Preserving sensitivity via the separate detection of SARS-CoV-2 targets allows the company’s highly effective, proven FTD SARS-CoV-2 Assay to perform without any compromise to sensitivity, maintaining key features of the top-performing assay.

The CLINITEST Rapid COVID-19 + Influenza A/B Antigen Test is a convenient 3-in-1 test that can be administered by a healthcare professional in virtually any medical setting, and provides reliable results in 15 minutes. With no instrumentation or equipment required, a single nasopharyngeal swab sample can differentiate between SARS-CoV-2, Influenza A, and Influenza B infections. This test provides high sensitivity and specificity (98.32%/99.60% for SARS-CoV-2, 88.57%/97.78% for Flu A, and 87.10%/97.87% for Flu B). Results can facilitate prompt self-isolation of infected patients, if deemed necessary, to prevent the spread of SARS-CoV-2 and influenza.

"As we enter cold and flu season, PCR and antigen testing options will allow clinicians to improve patient care by helping to identify the cause of respiratory illnesses that often present with similar symptoms,” said Sharon Bracken, Head of Diagnostics, Siemens Healthineers. "Enabling healthcare professionals to identify and differentiate among these infections in an efficient and timely manner may help to reduce the spread of seasonal respiratory viruses and SARS-CoV-2."

Related Links:
Siemens Healthineers

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more